Diagnostic and therapeutic technology assessment. Immunoaugmentative therapy
- PMID: 3373687
Diagnostic and therapeutic technology assessment. Immunoaugmentative therapy
Abstract
The scientific evidence to date, as well as the history of IAT, will allow no other conclusion than that IAT is unequivocally dangerous to its patients and of no proved value as a treatment for cancer. Physicians who know of patients receiving IAT must be aware of the high risk those people are incurring for life-threatening infections of several types.
Similar articles
-
Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment.Integr Cancer Ther. 2003 Jun;2(2):112-9. doi: 10.1177/1534735403002002003. Integr Cancer Ther. 2003. PMID: 15035898
-
Immunoaugmentative therapy. A primer on the perils of unproved treatments.JAMA. 1986 Jan 24-31;255(4):505-7. doi: 10.1001/jama.255.4.505. JAMA. 1986. PMID: 3001379
-
Immunoaugmentative therapy.Am Fam Physician. 1986 Dec;34(6):159-60. Am Fam Physician. 1986. PMID: 3788754 No abstract available.
-
Immunoaugmentative therapy. An unproven cancer treatment.JAMA. 1993 Oct 13;270(14):1719-23. doi: 10.1001/jama.270.14.1719. JAMA. 1993. PMID: 8411503 Review.
-
[Palliative immunotherapy of cancer].Ther Umsch. 2001 Jul;58(7):419-24. doi: 10.1024/0040-5930.58.7.419. Ther Umsch. 2001. PMID: 11508110 Review. German.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
